Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 27,500 shares, a decrease of 57.0% from the February 28th total of 63,900 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 284,400 shares, the short-interest ratio is currently 0.1 days.

Oncotelic Therapeutics Price Performance

OTLC opened at $0.07 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01. The stock’s 50 day simple moving average is $0.04 and its 200 day simple moving average is $0.03. The firm has a market cap of $28.44 million, a price-to-earnings ratio of -7.00 and a beta of -0.25. Oncotelic Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.07.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.